Meeting Banner
Abstract #4270

Liver Distribution and Delayed Phase Liver Enhancement using Mn-PyC3A

Derek Erstad1, Ian A Ramsay2, Bryan Fuchs1, Kenneth K Tanabe1, Peter Caravan2, and Eric M Gale2

1Surgical Oncology, Massachusetts General Hospital/ Harvard Medical School, Boston, MA, United States, 2Radiology/ Martinos Center, Massachusetts General Hospital, Charlestown, MA, United States

Mn-PyC3A was rationally designed as a Gd-free alternative to commercially available MRI contrast agents. Quantification of Mn excretion using rats shows that the agent is efficiently eliminated with a fractional clearance that is 85% renal and 15% hepatobiliary. Based on the substantial fractional hepatobiliary excretion, we hypothesized that Mn-PyC3A would provide delayed, liver specific contrast enhancement that can be used to identify liver tumors. Mn-PyC3A was demonstrated to provide delayed phase liver enhancement that rendered liver tumors conspicuously hypointense in a murine model of colorectal metastasis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here